Our Vision
Innovate Renal Therapeutics and provide the best solutions to renal patients
Our Mission
To become a prominent player helping patients fight kidney diseases with our deep knowledge, strong expertise and passion in product discovery and development
Founded in 2018, we are a global leading renal-focused biopharmaceutical company with the most comprehensive innovative renal portfolio.
We have developed a vertically-integrated platform encompassing research and development, manufacturing and commercialization of novel therapies primarily for kidney diseases and their complications, to bring greater therapeutic options to patients in China and globally.
We have built a diversified and balanced pipeline of drug candidates targeting a range of renal indications, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy (IgAN), diabetic kidney disease (DKD), focal segmental glomerulosclerosis (FSGS) and autosomal dominant polycystic kidney disease (ADPKD).
Our small molecule manufacturing site in Yangzhou has completed construction and has been in service. We have also established a dedicated commercialization team in China, responsible for the commercial promotion of renal products.
–
Kidney disease is defined as an abnormality of kidney structure or function, which can occur abruptly, and either resolve or become chronic. Chronic Kidney Disease (CKD) is a general term for heterogeneous disorders with variable clinical presentation, in part related to cause, severity and the rate of progression. Chronic kidney disease (CKD) is a condition that poses a growing threat to public health worldwide and has seen its incidence steadily rising in recent years. In China, the latest epidemiology data show that the prevalence of CKD in the adult population is as high as 10.8%, which amounts to a total patient population of 120 million with over one million renal patients at the end stage. Meanwhile, the diagnosis rate of CKD in China is just 12.5%, thus suggests enormous unmet patient need for diagnosis and treatment. The goal for the management of CKD is to halt or slow the rate of the progressive loss of the kidney function before they enter the end stage kidney failure, as well as to treat the complications reducing the morbidity and mortality when they enter the end stage kidney failure. The current standard of care for CKD management remains inadequate, the residual cardio-renal risk is still very high, and there is a huge unmet need for the new medication.
Alebund appreciates its employees, collaborators and partners with respect and consideration understanding needs and obligations as it is building an extensive and durable network globally.